Jinhui Ma | Medicine | Best Researcher Award

Dr. Jinhui Ma | Medicine | Best Researcher Award

Associate doctor | China-Japan Friendship Hospital | China

A dedicated orthopedic specialist at China-Japan Friendship Hospital, Department of Bone and Joint Surgery, serving as an Associate Chief Physician, with profound expertise in diagnosing and treating complex bone and joint conditions. His commitment to advancing orthopedic care is exemplified by his contributions to clinical research, academic publications, and medical education.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Extensive Clinical Expertise: Specializes in diagnosing and treating complex bone and joint diseases, with a focus on early treatment of osteonecrosis of the femoral head and hip preservation techniques.
  • Research Excellence: Has led notable research projects, including one funded by the Beijing Natural Science Youth Fund and another by the China-Japan Friendship Hospital, while contributing to three National Natural Science Foundation projects.
  • Publication Record: As first and co-first author, has published 17 SCI articles and nearly 8 core journal articles, showcasing a strong contribution to the academic community.
  • Academic Contributions: Participated in compiling three orthopedic books and contributed to the development of two utility model patents.
  • Recognition and Awards: Recipient of the “Outstanding Scientific Research Award” and “Excellent Graduate” award from Peking University, reflecting research excellence.
  • Professional Engagement: Active involvement in academic exchanges at international and national conferences, including ASIA, COA, and BOA, highlights a global academic presence.
  • Leadership Roles: Holds multiple editorial board positions and leadership roles in prestigious medical societies, further emphasizing professional recognition.

Education 🎓

He earned his Doctorate in Clinical Medicine from the Peking University Health Science Center, where he was recognized as an “Excellent Graduate” and received the “Outstanding Scientific Research Award.”

Experience đź’Ľ

He honed his skills at Queen Mary Hospital of the University of Hong Kong, specializing in joint replacement technology. He has extensive experience in early treatment of osteonecrosis of the femoral head, hip preservation, osteoarthritis, rheumatoid arthritis, hip dysplasia, motor system injuries, total knee and hip replacements, as well as knee and shoulder arthroscopy.

Research Interests On Medicine 🔬

His research focuses on the diagnosis and treatment of osteonecrosis of the femoral head, hip preservation techniques, advancements in joint replacement, and improving outcomes in complex bone and joint diseases.

Awards 🏆

  • Excellent Graduate of Peking University
  • Outstanding Scientific Research Award, Peking University
  • First Prize, Battle of 100 Groups, China Association for Health Promotion and Education
  • Third Prize, Chinese Orthopedic Good Doctor Reading Contest, Chinese Journal of Bone and Joint Surgery
  • Excellent Prize, Speech Contest (Beijing), Editorial Committee of the Chinese version of JBJS

Publications đź“–

He has authored 17 SCI articles and nearly 8 papers in core journals as the first or co-first author. Additionally, he participated in the compilation of three orthopedic books, such as “Osteonecrosis and Strategies for Diagnosis and Treatment of Joint Surgery.”

  • Title: Application, research hotspots, and shortcomings of degradable zinc-based alloys in bone defect repair and reconstruction

    • Authors: Liu Haoyang, Xie Qiang, Shen Mengran, Yue Debo, Wang Weiguo
    • Year: 2025
  • Title: Correction to: Extracellular Vesicles from BMSCs Prevent Glucocorticoid-Induced BMECs Injury by Regulating Autophagy via the PI3K/Akt/mTOR Pathway

    • Authors: Ma Jinhui, Shen Mengran, Yue Debo, Gao Fuqiang, Wang Bailiang
    • Year: 2024
  • Title: Editorial: New insight into immune cells in the development of non-traumatic osteonecrosis of the femoral head

    • Authors: Zhou Yu, Ma Jinhui, Zhang Qingyu, Wang Bailiang
    • Year: 2024
  • Title: Interleukin-33-mediated bone immunity

    • Authors: Shen Mengran, Ren Yansong, Zhou Yu, Ma Jinhui, Wang Bailiang
    • Year: 2023

Professional Contributions

He has led one Beijing Natural Science Youth Fund project, one China-Japan Friendship Hospital project, and contributed to three National Natural Science Foundation projects. His work also includes developing two utility model patents. Academically, he has presented at prestigious conferences like the Asian Association of Joint Replacement (ASIA), National Association of Orthopaedics (COA), and Beijing Orthopedic Association (BOA).

Professional Memberships đź”’

He serves as Secretary General of the Orthopedic Group of the Professional Committee of Translational Medicine of the Chinese Society of Microcirculation and holds memberships in:

  • Young and Middle-aged Editorial Committees of the Chinese Journal of Trauma, Chinese Journal of Reconstructive Surgery, Chinese Journal of Tissue Engineering, and Traditional Chinese Medicine Bone Setting.
  • Youth Working Committee of the Professional Committee of Translational Medicine, Chinese Society of Microcirculation.
  • Expert Committee on Bone Circulation and Osteonecrosis, Professional Committee of Shock Wave Medicine, Chinese Research Hospital Association.

Conclusion 🌟

His remarkable contributions to orthopedics, spanning clinical practice, research, and academic engagement, have made a lasting impact on the field. His passion for advancing orthopedic care and educating future generations continues to shape the future of bone and joint surgery.

Kyaw Thein | Health Sciences | Best Researcher Award

Assist. Prof. Dr. Kyaw Thein | Health Sciences | Best Researcher Award

MD | Comprehensive Cancer Centers of Nevada – Central Valley | United States

Dr. Kyaw Zin Thein, MD, is a highly skilled Medical Oncologist and Hematologist currently practicing at the Central Valley Treatment Center – Twain, affiliated with the Comprehensive Cancer Centers of Nevada. He also serves as a Clinical Assistant Professor at Touro University Nevada (TUN) and the University of Nevada, Las Vegas (UNLV). His dedication to patient care, research, and education has solidified his reputation as a leader in precision oncology and hematology.

Profile

Scopus

Google scholar

Orcid

Strengths for the Awards

  • Impressive Academic and Clinical Training
    • Dr. Kyaw Zin Thein has a robust academic background, including advanced fellowships in hematology, oncology, and investigational cancer therapeutics at world-renowned institutions such as MD Anderson Cancer Center.
    • A double board-certified oncologist and hematologist with certifications valid through 2029, showcasing his extensive expertise and commitment to maintaining professional standards.
  • Research Contributions and Publications
    • Author of 53 peer-reviewed journal articles, demonstrating significant contributions to advancing knowledge in oncology and hematology.
    • Published book chapters on cutting-edge topics like poly (ADP-ribose) polymerase inhibitors and multidisciplinary paradigms for head and neck cancer, reflecting his thought leadership in the field.
  • Teaching and Mentorship
    • Active roles as Clinical Assistant Professor at UNLV and Touro University Nevada, contributing to medical education.
    • Mentorship of numerous trainees, ranging from medical students to fellows, highlighting his commitment to shaping the next generation of oncologists and researchers.
  • Leadership and Awards
    • Held leadership roles, including Chief Fellow, Chief Resident, and committee member positions at esteemed institutions.
    • Recipient of multiple awards, such as the ASH Abstract Achievement Award and Research Recognition Awards, underscoring his excellence in research and clinical practice.

Education 🎓

Dr. Thein completed his M.B., B.S. (Doctor of Medicine) at the Institute of Medicine 1, Yangon, Myanmar (2004–2010). His advanced training includes:

  • Residency in Internal Medicine at Kingsbrook Jewish Medical Center, NY (2012–2015).
  • Fellowship in Hematology & Medical Oncology at Texas Tech University Health Sciences Center, TX (2016–2019).
  • Advanced Fellowships in Investigational Cancer Therapeutics and Oncologic Emergency Medicine at the University of Texas MD Anderson Cancer Center (2015–2020).

Professional Experience đź’Ľ

Dr. Thein has held numerous prestigious positions:

  • Medical Oncologist/Hematologist, Central Valley Treatment Center, Nevada (2023–present).
  • Assistant Professor of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science University (OHSU) (2020–2023).
  • Chief Fellow, Texas Tech University Health Sciences Center (2018–2019).
  • Member of multiple professional committees, including the Knight Cancer Institute’s Data and Safety Monitoring Committee.

Research Interests On Health Sciences🔬

Dr. Thein’s research focuses on precision oncology, investigational cancer therapeutics, and immunotherapy. He has contributed extensively to advancing cancer care through his work on targeted therapies, combination regimens, and innovative diagnostic methods.

Awards & Recognitions 🏆

Dr. Thein has received numerous accolades, including:

  • ASH Abstract Achievement Award, American Society of Hematology (2016).
  • Research Recognition Awards from Kingsbrook Jewish Medical Center (2014, 2015).
  • Excellence in Education Award, Myanmar American Medical Education Society (2011).

Publications 📚

  • Copper deficiency anemia
    • Authors: ZW Myint, TH Oo, KZ Thein, AM Tun, H Saeed
    • Year: 2018
    • Citations: 298
  • 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
    • Authors: G Han, G Yang, D Hao, Y Lu, K Thein, BS Simpson, J Chen, R Sun, et al.
    • Year: 2021
    • Citations: 136
  • Precision therapy for RET-altered cancers with RET inhibitors
    • Authors: KZ Thein, V Velcheti, BHM Mooers, J Wu, V Subbiah
    • Year: 2021
    • Citations: 112
  • Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center
    • Authors: I El Majzoub, A Qdaisat, KZ Thein, MA Win, MM Han, K Jacobson, et al.
    • Year: 2019
    • Citations: 91
  • Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism
    • Authors: MA Win, KZ Thein, A Qdaisat, SCJ Yeung
    • Year: 2017
    • Citations: 83
  • The contemporary management of cancers of the sinonasal tract in adults
    • Authors: R Thawani, MS Kim, A Arastu, Z Feng, MT West, NF Taflin, KZ Thein, R Li, et al.
    • Year: 2023
    • Citations: 74
  • Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
    • Authors: B Garmezy, J Gheeya, HY Lin, Y Huang, T Kim, X Jiang, KZ Thein, et al.
    • Year: 2022
    • Citations: 74
  • Therapeutics targeting mutant KRAS
    • Authors: KZ Thein, AB Biter, DS Hong
    • Year: 2021
    • Citations: 55
  • Pernicious anemia: Pathophysiology and diagnostic difficulties
    • Authors: TW Htut, KZ Thein, TH Oo
    • Year: 2021
    • Citations: 52
  • Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy
    • Authors: KZ Thein, TW Htut, S Ball, S Swarup, A Sultan, TH Oo
    • Year: 2020
    • Citations: 45

Conclusion 🌟

Dr. Kyaw Zin Thein is a visionary leader in oncology and hematology, with a career distinguished by cutting-edge research, impactful teaching, and exceptional clinical care. His dedication to advancing cancer therapies and mentoring future medical professionals underscores his commitment to transforming cancer treatment and education worldwide.